First authors/year Ref.
No. pts. Age/gender Onset of neuritis versus diagnosis of SS (years)* Nerves involved/clinical features Follow-up
Sjogren/1935 [10 ] 1 n.d. n.a. bil. VII n.a. Weber/1945 [11 ] 1 n.a. n.a. III n.a.
Spillane/1959 [12 ] 1 58 F n.a. bil. V n.a. Attwood/1961 [13 ] 1 50 F n.a. III–V–VII–IX Improv. with Cs Kaltreider/1969
[14 ] 4 45 F, 48 F, 52 F, 73 F +6; +2; +5; +14 sV (3), bil. (pt. 3); bil. I + PNS involv. (pt. 4) 1: chronic course, onset during Cs; 2, 4: Cs inefficacy; 3: response to Cs 1 55 F +8 I remission within 1 year Whaley/1972 [15 ] 1 27 F n.a. V Response to Cs and P.E. Hull/1984 [16 ] 1 33 F 0 V + PNS n.a. Vincent/1985 [17 ] 1 53 F +7 V–VII–IX-diplopia Recurrent ep. (6 in 7 years) Alexander/1986 [18 ] 16 Mean 50 F n.a. 7 II, 2 III, 1 V, 6 VI, 1 VII, 1 VIII n.a. Shimode/1986 [19 ] 1 n.a. n.a. II n.a. Serratrice/1986 [20 ] 1 58 F +4 V Cs 20 mg/day ineffective Malinow/1986 [21 ] 1 F n.a. V + d.r. ganglionitis n.a.
Mauch/1994 [22 ] 1 n.a. n.a. V n.a. Hankey/1987 [23 ] 1 78 F + (several years) V + PNS involv. n.a. Wise/1988 [24 ] 3 F − (1–6) II n.a. Laloux/1988 [25 ] 1 81 F n.a. V + d.r. ganglionitis n.a. Graus/1988 [26 ] 2 58 F, 75 F n.a. sV n.a. Phanthumchinda/ 1989 [27 ] 1 28 F 0 Multiple Resolved with Cs Uchihara/1989 [28 ] 1 n.a. n.a. bil. VII n.a. Mellgren/1989 [29 ] 5 n.a. n.a. V n.a. Andonopoulos/ 1990 [30 ] 3 n.a. n.a. V n.a. Flint/1990 [31 ] 1 n.a. n.a. bil. sV n.a. Mukai/1990 [32 ] 5 n.a. n.a. V n.a. Semah/1990 [33 ] 1 57 F −11 V Chronic course Berman/1990 [34 ] 1 10 F 0 II + CNS vasculitis Improv. with immunosuppressors Berault-Dupont/1992 [35 ] 1 59 F 0 VII Improv. to high dosage Cs Tesar/1992 [36 ] 3 20 F, 35 F, 41 F 0; −1; −2 II, bil. III-IV–VI (pt. 1), bil. II (pt. 2), II–IX-diplopia + CNS involv. (pt. 3) Resolution with high dosage Cs (pt. 1); improv. with high dosage Cs (pt. 2); recurrent, resolution of neuritis with Cs/CYC within 6 months (pt. 3) Soubrier/1993 [37 ] 4 n.a. n.a. V n.a. Pou Serradell/1993 [38 ] 1 63 F − (n.a.) III (8 ep.), multiple (5 ep.) Recurrent, responsive to Cs Güell/1993 [39 ] 1 n.a. 0 V n.a.
Mauch/1987 [40 ] 1 n.a. n.a. sV n.a. Bakouche/1994 [41 ] 1 49 M − (n.a.) Diplopia-V-tinnitus Recurrent (3 ep.) solving within 3 weeks Matsukawa/1995 [42 ] 1 56 F 0 V then IV–VI The first ep. autoresolved; the second with Cs Harada/1995 [43 ] 1 n.a. − (n.a.) II + acute transv. myelopathy Resistant to Cs Tajima/1997 [44 ] 9 Mean 54.9 F; 51 F n.a. 8 V, 4 bil.; 1 II n.a. Rojas-Rodriguez/1998 [45 ] 1 8 F − (n.a.) II Visual impairment not responsive to Cs, IVIG, CYC pulses Govoni/1999 [4 ] 2 51 F, 24 F +6; +2 VIII; III + cerebellar ataxia n.a. Dumas/1999 [46 ] 1 41 F n.a. sV n.a. Kuhl/1999 [47 ] 1 54 F +8 IV Improv. spontaneously within few weeks
Touze/1999 [48 ] 1 34 F (first ep.) −35; −2; 0; +2; + (n.a.) VI, VII, IX, laryngeal Recurrent ep., not improv. with Cs Oketani/1999 [49 ] 1 52 F +2 II Improv. to pulse Cs Wingerchuk/1999 [104 ] 4 n.a. n.a. II n.a. Chu/2000 [50 ] 1 54 F 0 IV-V Resolution with Cs and Aza within 4 weeks Urban/2001 [51 ] 1 53 F +1 V–IX-X Chronic course Hadithi/2001 [52 ] 1 41 F 0 VII Autoresolution after several days Lafitte/2001 [53 ] 1 n.a. n.a. V n.a. Kadota/2002 [54 ] 1 63 F 0 II Autoresolution within 6 months Maeda/2002 [55 ] 1 21 F 0 II Autoresolution Anaya/2002 [56 ] 1 n.a. n.a. II n.a. Yanagihara/2002 [57 ] 1 39 F 0 III n.a. Font/2003 [58 ] 6 Mean 58 F −4 to 0 V Chronic course besides oral Cs Delalande/2004 [59 ] 30 n.a. n.a. 2 I, 13 II, 5 V, 4 VII, 6 VIII n.a. Mori/2005 [60 ] 20 Mean 55.6 − (n.a.) 15 V, 1 VII, 5 multiple (III, V, VI, VII, IX, X, XII) 4/7 patients improv. with Cs Rousso/2005 [61 ] 1 40 F 0 VII Recurrent ep. that autoresolved, in 1 pt. with Cs/vit. B12 within 12 days
Oishi/2007 [62 ] 1 65 M 0 VI Autoresolved within 5 months Cardoso/2006 [63 ] 1 9 F −9; 0 bil. II 2 ep. 9 years apart, irreversible visual loss after initial response to Cs Galbussera/2007 [64 ] 1 79 F 0 III Resolution with Cs and IGIV within 2 months Pournaras/2007 [65 ] 1 38 M 0 bil. II Improv. with Cs
Gökçay/2007 [66 ] 1 20 F −10 II Cs/Aza resistant, switch to CYC Arabshahi/2006 [67 ] 1 11 F 0 bil. II + transv. myelitis Recurrent ep., transient improv. with Cs Barroso/2007 [68 ] 1 34 F −9 II + CNS involv. Recurrent ep., responsive to iv Cs Teo/2008 [69 ] 1 52 F 0 III n.a. Béjot/2008 [70 ] 1 53 F + (n.a.) bil. II + aseptic meningitis Improv. with CYC Lui/2008 [71 ] 1 59 M 0 III Resolved with Cs/Aza within 2 weeks Ii/2008 [72 ] 1 49 F 0 II Improv. with IVIG Javed/2008 [73 ] 2 n.a. n.a. II n.a. Pittock/2008 [74 ] 6 n.a. n.a. II n.a. Min/2009 [75 ] 6 n.a. n.a. II n.a. Ashraf/2009 [76 ] 1 47 F 0 V–IX–XII Resolved with Cs and MTX Kato/2009 [77 ] 1 25 F + (2) II + CNS involv. Improv. with high-dosage Cs Dellavance/2009 [78 ] 2 n.a. n.a. II n.a. Kim/2009 [79 ] 7 n.a. n.a. II Poor prognosis for high relapse rate Alhomoud/2009 [80 ] 10 Mean 40 F n.a. 9 II + CNS involv.; 1 VII n.a. Rabadi/2010 [81 ] 1 23 F 0 II n.a. Sakai/2010 [82 ] 1 77 M 0 III-bil.V-VI-VII Improv. with Cs Imbe/2010 [83 ] 1 31 F 0 II + acute myelitis Improv. with Cs/P.E. Nascimento/2010 [84 ] 2 n.a. −10; −0.5 V n.a. Chourkani/2010 [85 ] 2 43 F, 48 F 0 II (bil. 1 pt.) Improv. with Cs/immunosuppressors Massara/2010 [86 ] 3 48, 50, 74 F +5, +6, +16 years later 2 II, 1 VII Resolution with iv Cs Cojocaru/2011 [87 ] 1 50 F +0.7; +2 II then V 1° ep.: improv. with Cs/IVIG; 2° ep.: Cs-resistant
Niţescu/2011 [88 ] 2 n.a. + (n.a.) II n.a. Yadav/2011 [89 ] 1 26 F + (several years) bil. II n.a. Koga/2011 [90 ] 1 31 F 0 II + acute myelitis Improv. with P.E., Cs-resistant Gono/2011 [91 ] 7 Mean 44 F n.a. 3 II (1 + CNS involv.), 2 V, 1 VII, 1 IX-X n.a. Kolfenbach/2011 [92 ] 6 n.a. n.a. II Recurrent ep. Estiasari/2012 [93 ] 10 n.a. n.a. II n.a. Horai/2012 [94 ] 8 63 F, 52 M, 43 F, 61 F, 51 F, 55 F, 45 F, 35 F 0 (first case); n.a. V (4 bil.) Improv. with Cs/tacrolimus (1); Improv. with Cs (1); Improv. with symptomatic treat (3); resist. to Cs (1); recurrent (1) Tan/2012 [95 ] 1 56 F 0 bil. II Permanent visual impairment Maruta/2012 [96 ] 1 89 F 0 II Improv. with iv Cs Mallucci/2012 [97 ] 1 74 F 0 bil. II n.a. Teixeira/2013 [7 ] 4 Mean 47.9 F n.a. 2 II, V, VI, 2 VII Cs almost effective Briani/2013 [98 ] 1 66 F +5 V n.a. Flanagan/2013 [99 ] 1 64 M 0 V n.a. Tang/2013 [100 ] 8 Mean 34.7 F 0 II Recurrent (3 pts), response to Cs/immunosuppressors Present cases 2 40 F, 54 F −6; +8 II; phrenic nerve Improvement with Cs (40 F), with IVIG (54 F) TOTAL 267 F/M: 20.8 Mean age:
years 4 I, 123 II, 8 III, 4 IV, 95 V, 17 VI, 23 VII, 9 VIII, 11 IX, 8 X, 0 XI, 6 XII (
)